Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer

Next Previous
Trial Profile

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Doxorubicin; Paclitaxel
  • Indications Carcinoma; Endometrial cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-775
  • Sponsors Eisai Inc; Merck Sharp & Dohme

    • Most Recent Events

    • 21 Dec 2023 According to an Eisai Co Ltd media release, company received public listing for patients with advanced endometrial carcinoma that is not MSI-H or dMMR
    • 21 Dec 2023 According to an Eisai Co Ltd media release, company received the notice of compliance issuance from Health Canada for KEYTRUDA plus LENVIMA versus chemotherapy in patients with advanced endometrial carcinoma who had been previously treated with at least one prior platinum based chemotherapy regimen in any setting
    • 24 Oct 2023 Results of exploratory analysis in pts who completed 2 yrs of pembro and continued LEN at the final prespecified OS analysis (cutoff: 1 Mar 22, n=411) presented at the 48th European Society for Medical Oncology Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top